Lattice Biologics (TSXV:LBL.H) Cash, Cash Equivalents, Marketable Securities : C$0.00 Mil (As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Cash, Cash Equivalents, Marketable Securities?

Lattice Biologics's quarterly cash, cash equivalents, marketable securities increased from Dec. 2020 (C$0.03 Mil) to Mar. 2021 (C$0.03 Mil) but then stayed the same from Mar. 2021 (C$0.03 Mil) to Jun. 2021 (C$0.00 Mil).

Lattice Biologics's annual cash, cash equivalents, marketable securities increased from Sep. 2018 (C$0.01 Mil) to Sep. 2019 (C$0.02 Mil) and increased from Sep. 2019 (C$0.02 Mil) to Sep. 2020 (C$0.08 Mil).

Lattice Biologics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Lattice Biologics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Cash, Cash Equivalents, Marketable Securities Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.07

0.02

0.01

0.02

0.08

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															0.03	0.08	0.03	0.03	-

Lattice Biologics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Lattice Biologics (TSXV:LBL.H) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Lattice Biologics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines